Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients.

These results are the first US estimates for the incidence of thrombotic and rare events of interest in a large, commercially insured US population. Findings provide a critically important reference for determining excess morbidity associated with COVID-19 and more generally for vaccine pharmacovigilance.